60 Degrees Pharmaceuticals (NASDAQ:SXTP) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of 60 Degrees Pharmaceuticals (NASDAQ:SXTP) from a sell rating to a hold rating in a report published on Saturday morning.

Several other equities analysts also recently weighed in on the stock. HC Wainwright raised their target price on shares of 60 Degrees Pharmaceuticals from $6.00 to $24.00 and gave the company a “buy” rating in a report on Tuesday, January 27th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a report on Friday, March 27th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, 60 Degrees Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $17.60.

60 Degrees Pharmaceuticals Price Performance

NASDAQ:SXTP opened at $1.86 on Friday. 60 Degrees Pharmaceuticals has a 52-week low of $1.29 and a 52-week high of $17.68. The stock has a fifty day simple moving average of $2.92 and a 200-day simple moving average of $3.83. The company has a market capitalization of $4.91 million, a PE ratio of -0.13 and a beta of 3.27.

Key Stories Impacting 60 Degrees Pharmaceuticals

Here are the key news stories impacting 60 Degrees Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised multi‑year EPS forecasts sharply (FY2026 from ($5.92) to ($2.21); FY2027 to ($0.54); FY2028 to ($0.44)) while keeping a “Buy” rating and a $24.00 price target — the upgrade in estimates and high price target support a potential re‑rating if clinical or operational progress continues. HC Wainwright Research Note
• Positive Sentiment: Zacks upgraded SXTP to a Zacks Rank #2 (Buy), signaling growing optimism among independent research providers and adding to buying interest from model‑based and retail investors. 60 Degrees Pharmaceuticals Inc. (SXTP) Upgraded to Buy
• Neutral Sentiment: 60 Degrees will gain media exposure with interviews airing on the RedChip “Small Stocks, Big Money” show on Bloomberg TV — this can increase awareness and short‑term volume but does not itself change fundamentals. Bloomberg TV Interview Announcement
• Negative Sentiment: Material risks remain: SXTP is loss‑making (consensus negative EPS), has a very small market cap and low average trading volume — these factors make the stock volatile and can limit sustained upside even after bullish research notes.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.